Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Income (2016 - 2025)

Historic Operating Income for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.2 million.

  • Rocket Pharmaceuticals' Operating Income rose 2474.22% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 851.46%. This contributed to the annual value of -$273.2 million for FY2024, which is 521.68% down from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Operating Income is -$52.2 million, which was up 2474.22% from -$71.1 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Operating Income registered a high of -$34.0 million during Q2 2021, and its lowest value of -$73.7 million during Q2 2024.
  • Moreover, its 5-year median value for Operating Income was -$62.7 million (2024), whereas its average is -$58.5 million.
  • Over the last 5 years, Rocket Pharmaceuticals' Operating Income had its largest YoY gain of 2516.0% in 2021, and its largest YoY loss of 8127.58% in 2021.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Operating Income stood at -$44.3 million in 2021, then crashed by 55.83% to -$69.1 million in 2022, then grew by 8.4% to -$63.3 million in 2023, then grew by 0.92% to -$62.7 million in 2024, then grew by 16.66% to -$52.2 million in 2025.
  • Its Operating Income was -$52.2 million in Q3 2025, compared to -$71.1 million in Q2 2025 and -$64.4 million in Q1 2025.